Overview
Pulmonary necrosis refers to the death of lung tissue, often secondary to severe infections, trauma, or inflammatory processes. Tumor necrosis factor (TNF) can contribute to this condition through mechanisms involving monocyte activation and hypercoagulability leading to thrombotic vascular occlusion 1.Diagnosis
Elevated inflammatory markers indicative of systemic inflammation 1
Imaging findings such as consolidation, cavitation, or ground-glass opacities on CT scans
Histopathological evidence of tissue necrosis and thrombotic changes 1Management
Supportive care including mechanical ventilation support as needed
Antimicrobial therapy targeting identified pathogens
Anti-inflammatory agents such as corticosteroids for severe inflammation 1
Management of hypercoagulability with anticoagulation therapy if indicated 1Special Populations
Pregnancy: Limited data; close monitoring and individualized management strategies are crucial 1
Pediatrics: Tailored supportive care and targeted antimicrobial therapy based on age-specific pharmacokinetics 1
Elderly: Increased vigilance for complications; consider frailty and comorbidities in treatment planning 1
Comorbidities: Focus on managing underlying conditions that may exacerbate pulmonary necrosis 1Key Recommendations
Monitor and manage hypercoagulability states with appropriate anticoagulation therapy in patients with pulmonary necrosis due to TNF-mediated mechanisms (Evidence: Moderate) 1
Initiate targeted antimicrobial therapy based on microbiological findings to address infectious causes of pulmonary necrosis (Evidence: Expert opinion) 1
Employ corticosteroids cautiously in severe cases to control inflammation, balancing benefits against potential side effects (Evidence: Moderate) 1References
1 Spillert CR, Sun S, Ponnudurai R, Miller MA, Lazaro EJ. Tumor necrosis factor-induced necrosis: a monocyte-mediated hypercoagulable effect. Journal of the National Medical Association 1995. link